JMP Securities raised the price target to $105 from $90 on Haemonetics Corporation (NYSE:HAE) with a Market Outperform rating following the release of…
November 8, 8:27 AM
JMP Securities analyst David Turkaly maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $90 to $105.
October 13, 1:09 PM
Over the past 3 months, 6 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
October 13, 5:22 AM
Mizuho analyst Anthony Petrone initiates coverage on Haemonetics (NYSE:HAE) with a Buy rating and announces Price Target of $90.
September 12, 6:29 PM
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate…